Article

AIP: PEER VIEWPOINT: The Toxicity of Chemotherapy and Radiotherapy on the Central Nervous System

In this issue of The Journal of Supportive Oncology, Rinne and collaborators present a welcome update on this often neglected aspect of neuro-oncology. They present a complex problem in an easy flow of ideas, beginning with the neurotoxicity of radiotherapy, then including the contribution of chemotherapy and novel therapies targeted to CNS morbidity.



 

Peer viewpoint

The Toxicity of Chemotherapy and Radiotherapy on the Central Nervous System

  • Ivo W. Tremont-Lukats, MD
  • http://dx.doi.org/10.1016/j.suponc.2012.04.001,

Central neurotoxicity of chemotherapy and radiotherapy is so frequent that every clinician should recognize and treat this complication, preferably with a neurologist experienced in these cases. Unfortunately, in most neurology and oncology training programs in the United States, there is very little exposure to the central neurotoxicity of anticancer drugs and other modalities. Yet, the importance of the topic is high and will always be.

One of the main forces driving the knowledge behind this area began at the Memorial Sloan-Kettering Cancer Center with Posner [1] and [2] and in Europe with Hildebrand. [3] Others have understood that the effective management of CNS toxicity is as important as the treatment of brain tumors in neuro-oncology and are now making efforts in spreading the message: we must learn to recognize, treat, or prevent the neurotoxicity of anticancer therapies. In the past 10 years, there have been reviews on neurological complications; [4] and [5] and yet there is still little interest, and research is a low priority.

In this issue of The Journal of Supportive Oncology , Rinne and collaborators present a welcome update on this often neglected aspect of neuro-oncology. They present a complex problem in an easy flow of ideas, beginning with the neurotoxicity of radiotherapy, then including the contribution of chemotherapy and novel therapies targeted to CNS morbidity. This review is thorough, up to date, and one of the few published by a nonneurological journal. Enjoy. 1

References2

  1. J.B. Posner. Neurological complications of systemic cancer. Med Clin North Am. 1979;63(4):783–800.
  2. R.A. Patchell, J.B. Posner. Neurologic complications of systemic cancer. Neurol Clin . 1985;3(4):729–750.
  3. J. Hildebrand. Neurological Complications of cancer chemotherapy. Curr Opin Oncol. 2006;18(4):321–324.
  4. S.R. Plotkin, P.Y. Wen. Neurologic complications of cancer therapy. Neurol Clin . 2003;21(1):279–318.
  5. C. Soussain, D. Ricard, J.R. Fike, J.J. Mazeron, D. Psimaras, J.Y. Delattre.

    CNS complications of radiotherapy and chemotherapy. Lancet. 2009;374(9701):1639–1651.

Commentary on “Central Nervous System Complications of Cancer Therapy” by Rinne, Lee, and Wen (page ___)

Published Online:

Corresponding Author: Ivo W. Tremont-Lukats, MD, Neuro-Oncology Department, MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030

Conflict of Interest Disclosures: The author has completed and submitted the ICMJE for Disclosure of Potential Conflicts of Interest and none were reported.

PubMed ID in brackets

Vitae

Dr Tremont-Lukats is an Assistant Professor in the Neuro-Oncology Department of the University of Texas MD Anderson Cancer Center, Houston, Texas

Copyright © 2012 Published by Elsevier Inc.

Recommended Reading

Wearable Electric Fields Device Approved for Brain Tumors
MDedge Hematology and Oncology
Genetic Marker Predicts Taxane-Induced Neuropathy
MDedge Hematology and Oncology
Treatment of recurrent high-grade gliomas
MDedge Hematology and Oncology
Cancer-Protective Effects Seen for Type IV Allergies
MDedge Hematology and Oncology
Intensified Temozolomide Fails to Hike Glioblastoma Survival
MDedge Hematology and Oncology
Release of Glutamate From Gliomas Sparks Seizures
MDedge Hematology and Oncology
Protons Added to Photon Radiation Improve Chordoma Control
MDedge Hematology and Oncology
Gamma Knife Surgery Cuts Seizures in Tumor Patients
MDedge Hematology and Oncology
MR Spectroscopy May Give Glioma Prognosis, Location
MDedge Hematology and Oncology
In the Pipeline: Immunotherapy Slows Childhood Gliomas
MDedge Hematology and Oncology